A Phase III, randomized, double-blind, parallel-group, active control. multi-centre study to assess safety and efficacy of CIP-Isotretinoin in pediatric patients with severe recalcitrant nodular acne

Trial Profile

A Phase III, randomized, double-blind, parallel-group, active control. multi-centre study to assess safety and efficacy of CIP-Isotretinoin in pediatric patients with severe recalcitrant nodular acne

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jan 2015

At a glance

  • Drugs Isotretinoin (Primary)
  • Indications Nodulocystic acne
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top